SAN DIEGO, December 1, 2015 /PRNewswire/ --
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) today announced that Harry Lander, PhD, currently President of Regen Biopharma, Inc., would also serve as Chief Scientific Officer of the company. Regen also announced that five top researchers have agreed to serve on the company's scientific advisory board. Those researchers are Francesco Marincola, M.D., Ralph Nachman, M.D., Stefano Bertuzzi, Ph.D., Helen Sabzevari, Ph.D. and Lorraine Gudas, Ph.D.
Dr. Lander received a Bachelor of Science degree in biochemistry and a Bachelor of Arts degree in chemistry from State University at Stony Brook in 1987, a doctorate in Biochemistry from Cornell University Graduate School of Medical Sciences in 1992 and an MBA in finance from the New York University Stern School of Business in 2001. Dr. Lander has strong experience as both a researcher and administrator, having served in these positions at Cornell University as well as the Sidra Medical and Research Center in Qatar.
The Regen BioPharma, Inc. scientific advisory board, now numbering 16, will work closely with Dr. Lander and the rest of his management team to advance the firm's small molecule and immuno-oncological therapeutics.
Francesco Marincola, M.D., one of the most recognized tumor immunologists in the world, serves as Chief Research Officer at Sidra Medical and Research Center.
Ralph Nachman, M.D., a renowned hematologist, is a member of the Institute of Medicine and University Professor and former Chairman of Medicine at NY Presbyterian/Weill Cornell Medical Center.
Stefano Bertuzzi, Ph.D., is Executive Director at American Society for Cell Biology and was a senior scientific executive at the National Institutes of Health where he served as Director of Policy and Planning for the Mental Health Institute.
Helen Sabzevari, Ph.D., one of the key leaders in the world in developing immunotherapies, was head of immuno-oncology, global research and early development at MerckSerono.
Lorraine Gudas, Ph.D., is one of the top experts in the world on nuclear receptors and is extremely familiar with the NR2F family of orphan receptors. She is a professor and chairman of the Department of Pharmacology at Weill Cornell Medical College.
"We're putting together a life science dream team," said company Chairman & CEO David Koos. "This is the high-level team we want to shepherd our stem cell and immuno-oncology therapeutics, as well as our novel cancer stem cell therapeutic targets, through development and trials and, ultimately, to the people who need them."
Lander assumes the position of Chief Scientific Officer from Dr. Thomas Ichim, co-founder of Regen BioPharma Inc., who elected to transition to the role of Senior Research Consultant after he and David Koos recruited Dr. Lander as President.
"As the pipeline of the company matures, we need to ensure that we have the right scientific advisors supporting us," said Lander. "Tom is an incredibly creative scientist, and retaining him as our senior research consultant allows us to maintain continuity in our programs and continue to benefit from his remarkable energy and creativity."
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy, telomeres and small molecule therapies for treating cancers, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
The Dorsee Company
SOURCE Regen BioPharma Inc.